Binder M, Nandakumar B, Rajkumar SV, Kapoor P, Buadi FK, Dingli D, et al. Mortality trends in multiple myeloma after the introduction of novel therapies in the United States. Leukemia. 2022;36:801–8.

Article  PubMed  Google Scholar 

Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387:132–47.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Sperling AS, Guerra VA, Kennedy JA, Yan Y, Hsu JI, Wang F, et al. Lenalidomide promotes the development of TP53 -mutated therapy-related myeloid neoplasms. Blood. 2022;140:1753–63.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chung A, Liedtke M. Therapy-related myeloid neoplasms after treatment for plasma-cell disorders. Best Pract Res Clin Haematol. 2019;32:54–64.

Article  PubMed  Google Scholar 

Palumbo A, Bringhen S, Kumar SK, Lupparelli G, Usmani S, Waage A, et al. Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncol. 2014;15:333–42.

Article  PubMed  CAS  Google Scholar 

McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279–89.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Jones JR, Cairns DA, Menzies T, Pawlyn C, Davies FE, Sigsworth R, et al. Maintenance lenalidomide in newly diagnosed transplant eligible and non-eligible myeloma patients; profiling second primary malignancies in 4358 patients treated in the Myeloma XI Trial. eClinicalMedicine. 2023;62:102099.

Article  PubMed  PubMed Central  Google Scholar 

Parrondo RD, Reljic T, Iqbal M, Ayala E, Kharfan‐Dabaja MA, Kumar A, et al. Efficacy of proteasome inhibitor‐based maintenance following autologous transplantation in multiple myeloma: a systematic review and meta‐analysis. Eur J Haematol. 2021;106:40–8.

Article  PubMed  CAS  Google Scholar 

Soerensen JF, Aggerholm A, Kerndrup GB, Hansen MC, Ewald IKL, Bill M, et al. Clonal hematopoiesis predicts development of therapy-related myeloid neoplasms post-autologous stem cell transplantation. Blood Adv. 2020;4:885–92.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Diamond BT, Ziccheddu B, Maclachlan KH, Taylor J, Boyle EM, Arango Ossa JE, et al. Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures. Blood. 2023;141:2359–71.

Awada H, Gurnari C, Visconte V, Durmaz A, Kuzmanovic T, Awada H, et al. Clonal hematopoiesis-derived therapy-related myeloid neoplasms after autologous hematopoietic stem cell transplant for lymphoid and non-lymphoid disorders. Leukemia. 2024;38:1266–74.

Article  PubMed  PubMed Central  Google Scholar 

Nadiminti K, Sidiqi MH, Meleveedu K, Alkhateeb HB, Hogan WJ, Litzow M, et al. Characteristics and outcomes of therapy-related myeloid neoplasms following autologous stem cell transplantation for multiple myeloma. Blood Cancer J. 2021;11:63.

Article  PubMed  PubMed Central  Google Scholar 

Zanwar S, Jacob EK, Greiner C, Pavelko K, Strausbauch M, Anderson E, et al. The immunome of mobilized peripheral blood stem cells is predictive of long-term outcomes and therapy-related myeloid neoplasms in patients with multiple myeloma undergoing autologous stem cell transplant. Blood Cancer J. 2023;13:151.

Article  PubMed  PubMed Central  Google Scholar 

Heuser M. Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment? Hematology. 2016;2016:24–32.

Article  PubMed  PubMed Central  Google Scholar 

Jentzsch M, Grimm J, Bill M, Brauer D, Backhaus D, Goldmann K, et al. ELN risk stratification and outcomes in secondary and therapy-related AML patients consolidated with allogeneic stem cell transplantation. Bone Marrow Transplant. 2021;56:936–45.

Article  PubMed  CAS  Google Scholar 

Litzow MR, Tarima S, Pérez WS, Bolwell BJ, Cairo MS, Camitta BM, et al. Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood. 2010;115:1850–7.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Metheny L, Callander NS, Hall AC, Zhang M-J, Bo-Subait K, Wang H-L, et al. Allogeneic transplantation to treat therapy-related myelodysplastic syndrome and acute myelogenous leukemia in adults. Transplant Cell Ther. 2021;27:923.e1–923.e12.

Article  PubMed  CAS  Google Scholar 

Kröger N, Eikema D, Köster L, Beelen D, de Wreede LC, Finke J, et al. Impact of primary disease on outcome after allogeneic stem cell transplantation for transformed secondary acute leukaemia. Br J Haematol. 2019;185:725–32.

Article  PubMed  Google Scholar 

Robin M, De Wreede LC, Schroeder T, Stölzel F, Kröger N, Koster L, et al. Primary cancer matters in therapy-related myeloid neoplasm patients receiving allogeneic hematopoietic cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT. HemaSphere. 2023;7:e851.

Article  PubMed  PubMed Central  Google Scholar 

Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–33.

Article  PubMed  PubMed Central  Google Scholar 

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.

Article  PubMed  Google Scholar 

Baranwal A, Chhetri R, Yeung D, Clark M, Shah S, Litzow MR, et al. Factors predicting survival following alloSCT in patients with therapy-related AML and MDS: a multicenter study. Bone Marrow Transplant. 2023;58:769–76.

Article  PubMed  Google Scholar 

Shah MV, Tran ENH, Shah S, Chhetri R, Baranwal A, Ladon D, et al. TP53 mutation variant allele frequency of ≥10% is associated with poor prognosis in therapy-related myeloid neoplasms. Blood Cancer J. 2023;13:51.

Article  PubMed  PubMed Central  Google Scholar 

Mouhieddine TH, Sperling AS, Redd R, Park J, Leventhal M, Gibson CJ, et al. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020;11:2996.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Nabergoj M, Mauff K, Beelen D, Ganser A, Kröger N, Stölzel F, et al. Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2022;57:1072–8.

Article  PubMed  Google Scholar 

Nabergoj M, Eikema D-J, Koster L, Platzbecker U, Sockel K, Finke J, et al. Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT. Bone Marrow Transplant. 2024;59:395–402.

Article  PubMed  CAS  Google Scholar